1430611-23-6
Chemical Structure
CCG-203586
- CAS No.: 1430611-23-6
- Formula:C26H32N2O4
- Molecular Weight:436.55
IUPAC Name: 2-(2,3-dihydro-1H-inden-2-yl)-N-((1R,2R)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)acetamide
InChIKey: WXPGOGVMRCVPDZ-ATIYNZHBSA-N
SMILES: [C@@H]([C@@H](CN1CCCC1)NC(CC2CC=3C(C2)=CC=CC3)=O)(O)C=4C=C5C(=CC4)OCCO5
Biological Activity: CCG-203586 is a brain-penetrant glucosylceramide synthase (GCS) inhibitor. CCG-203586 reduces GCS production and brain levels, blocks the first committed step in ganglioside biosynthesis, and lowers downstream ganglioside levels. CCG-203586 can be used for the research of Tay-Sachs, Sandhoff disease, and types 2 and 3 Gaucher disease[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CCG-203586 | CCG-203586 is a brain-penetrant glucosylceramide synthase (GCS) inhibitor. CCG-203586 reduces GCS production and brain levels, blocks the first committed step in ganglioside biosynthesis, and lowers downstream ganglioside levels. CCG-203586 can be used for the research of Tay-Sachs, Sandhoff disease, and types 2 and 3 Gaucher disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Wilson MW, et al. Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors as Substrate Reduction Therapy for Gaucher Disease Type 3. ACS Chem Neurosci. 2020;11(20):3464-3473. [Content Brief]
- [2]. Larsen SD, et al. Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. J Lipid Res. 2012;53(2):282-291. [Content Brief]
- [3]. Arthur JR, et al. Ethylenedioxy-PIP2 oxalate reduces ganglioside storage in juvenile Sandhoff disease mice. Neurochem Res. 2013;38(4):866-875. [Content Brief]
Keywords
